The effect of selected pre-analytical phase variables on plasma thromboxane A2 measurements in humans

International Journal of Laboratory Hematology

Volumn 35, Issue 1, 2013, Pages 92-100

  Sadilkova, L ^a   Paluch, Z ^a   Mottlova, J ^a   Bednar, F ^b   Alusik, S ^a  

^a FAKULTNÍ THOMAYEROVA NEMOCNICE   (Czech Republic)

^b CHARLES UNIVERSITY   (Czech Republic)

Author keywords

11 dehydrothromboxane B2; Anticoagulant; Enzyme immunosorbent assay; Plasma Thromboxane B2; Platelets

Indexed keywords

11 OXOTHROMBOXANE B2; CITRATE TRISODIUM; THROMBOXANE A2; THROMBOXANE B2;

ANTICOAGULATION; ARTICLE; BLOOD CLOTTING PARAMETERS; BLOOD STORAGE; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME IMMUNOASSAY; HUMAN; HUMAN TISSUE; PRIORITY JOURNAL;

ANTICOAGULANTS; ASPIRIN; BLOOD PLATELETS; CITRATES; CYCLOOXYGENASE INHIBITORS; HUMANS; IMMUNOENZYME TECHNIQUES; PLATELET AGGREGATION INHIBITORS; SPECIMEN HANDLING; TEMPERATURE; THROMBOXANE A2; THROMBOXANE B2; TIME FACTORS;

EID: 84872272116     PISSN: 17515521     EISSN: 1751553X     Source Type: Journal    
DOI: 10.1111/j.1751-553X.2012.01458.x     Document Type: Article

References (22)

1. Harrison P, Segal H, Silver L, Syed A, Cuthbertson FC, Rothwell PM. Lack of reproducibility of assessment of aspirin responsiveness by optical aggregometry and two platelet function tests. Platelets 2008;19:119-24.
2. Berkman NY, Michaeli R, Or R, Eldor A. EDTA-dependent pseudothrombocytopenia: a clinical study of 18 patients and a review of the literature. Am J Hematol 1991;36:195-201.
3. Kottke-Marchant K, Bahit MC, Granger CB, Zoldhelyi P, Ardissino D, Brooks L, Griffin JH, Potthoff RF, Van de Werf F, Califf RM, Topol EJ. Effect of hirudin vs heparin on haemostatic activity in patients with acute coronary syndromes; the GUSTO-IIb haemostasis substudy. Eur Heart J 2002;23:1202-12.
4. Schneider DJ, Tracy PB, Mann KG, Sobel BE. Differential effects of anticoagulants on the activation of platelets ex vivo. Circulation 1997;96:2877-83.
5. Reid JT, LaRussa VF, Esteban G, Clear M, Davies L, Shea S, Gorogias M. Cooling and freezing damage platelet membrane integrity. Cryobiology 1999;38:209-24.
6. Hamberg M, Svensson J, Samuelsson B. Thromboxanes: a new group of biologically active compounds derived from prostaglandin endoperoxides. Proc Natl Acad Sci USA 1975;72:2994-8.
7. Eikelboom JW, Hirsh J, Weitz JI, Johnston M, Yi Q, Yusuf S. Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events. Circulation 2002;105:1650-5.
8. Catella FD, Healy Lawson JA, FitzGerald GA. 11-Dehydrothromboxane B2: a quantitative index of thromboxane A2 formation in the human circulation. Proc Natl Acad Sci USA 1986;83:5861-5.
9. Krasopoulos G, Brister SJ, Beattie WS, Buchanan MR. Aspirin "resistance" and risk of cardiovascular morbidity: systematic review and meta-analysis. BMJ 2008;336:195-8.
10. Lordkipanidze M, Pharand C, Schampaert E, Turgeon J, Palisaitis DA, Diodati JG. A comparison of six major platelet function tests to determine the prevalence of aspirin resistance in patients with stable coronary artery disease. Eur Heart J 2007;28:1702-8.
11. Viinikka L, Ylikorkala O. Measurement of thromboxane B2 in human plasma or serum by radioimmunoassay. Prostaglandins 1980;20:759-66.
12. Patrono C, Ciabattoni G, Pugliese F, Pierucci A, Blair IA, FitzGerald GA. Estimated rate of thromboxane secretion into the circulation of normal humans. J Clin Invest 1986;77:590-4.
13. Samuelsson B, Granstrom E, Green K, Hamberg M, Hammarstrom S. Prostaglandins. Annu Rev Biochem 1975;44:669-95.
14. Magee LS. Pre-Analytical Variables in the Chemistry Laboratory. Franklin Lakes, NJ: Becton Dickinson Lab Notes; 2005:1-4.
15. Guder WG. The Quality of Diagnostic Samples. Recommendations of the working group on pre-analytical variables of the German Society for Clinical Chemistry and the German Society for Laboratory Medicine. Germany: Darmstadt; 2000.
16. Cattaneo M. The clinical relevance of response variability to antiplatelet therapy. Hematology 2011;1:70-5.
17. Keller F, Hericks K, Schuller I, Passfall J, Joerres A, Meinhold H. Thromboxane B2 blood levels and incipient system clotting in heparin free hemodialysis. ASAIO J 1995;41:173-7.
18. Kyrle PA, Westwick J, Scully MF. Investigation of the interaction of blood platelets with the coagulation systém. Thromb Haemost 1987;57:62-6.
19. Patrignani P, Filabozzi P, Patrono C. Selective cumulative inhibition of platelet thromboxane production by low-dose aspirin in healthy subjects. J Clin Invest 1982;69:1366-72.
20. Golanski J, Pietrucha T, Baj Z, Greger J, Watala C. Molecular insights into the anticoagulant-induced spontaneous activation of platelets in whole blood-various anticoagulants are not equal. Thromb Res 1996;83:199-216.
21. Maree AO, Curtin RJ, Dooley M, Conroy RM, Crean P, Cox D, Fitzgerald DJ. Platelet response to low-dose enteric-coated aspirin in patients with stable cardiovascular disease. J Am Coll Cardiol 2005;46:1258-63.
22. Inui H, Kitami Y, Tani M, Kondo T, Inagami T. Differences in signal transduction between platelet-derived growth factor (PDGF) and receptors in vascular smooth muscle cells. J Biol Chem 1994;269:30546-52.